considerable overlap, and sweat chloride concentration cannot be used to identify cystic fibrosis heterozygotes. Pancreatic function in cystic fibrosis heterozygotes has not been evaluated with sensitive tests, but neutral fat excretion is normal.2 No pulmonary expression of the cystic fibrosis gene in heterozygotes has been clearly demonstrated.1 8 Pulmonary abnormalities can, however, be provoked in cystic fibrosis heterozygotes by a nonspecific bronchial irritant: about one third of symptomless, medication free, young heterozygotes for cystic fibrosis have increased bronchial reactivity to methacholine.9 To pursue this observation, we investigated respiratory symptoms in a large number of unselected individuals heterozygous for cystic fibrosis to test the hypothesis that, if non-specific airway reactivity is more prevalent in cystic fibrosis heterozygotes, then the cardinal symptom of airway reactivity-wheezing-will also be more prevalent. It seemed important to test whether airway reactivity Pulmonary abnormalities in obligate heterozygotes for cystic fibrosis and its symptom are indeed prevalent iweystic fibrosis heterozygotes as a group, for airway reactivity has been postulated to be a risk factor for development and progression of obstructive airways disease. 10 -13 If they have a high prevalence of airway reactivity, cystic fibrosis heterozygotes might constitute a sizable (4-5% of the white population) group at risk for airways obstruction. Methods
SUBJECTS
Subjects gave consent to participate in this study, which was approved by the Institutional Review Board. Parents of children with cystic fibrosis were invited to participate as they accompanied their child on a clinic visit, visited the child in hospital, or volunteered to report on two special clinic days for the study. For all the children the diagnosis of cystic fibrosis was based on a sweat chloride concentration over 60 mEq(mmol)/l and the presence of either pancreatic insufficiency or chronic obstructive pulmonary disease, or both. The only criteria for entry into the study for the parents were the biological relation to a child with cystic fibrosis and willingness to fill in the questionnaire and undergo spirometry. All available parents who visited the hospital during the study period participated (some, who visited only at weekends or late at night, were never contacted). The controls were the parents of children with congenital or acquired heart or circulatory disease attending the same ambulatory practice or admitted to the same hospital as the children with cystic fibrosis. The only entry criteria were the biological relationship to an ill child and willingness to participate. All parents available during the scheduled clinics we attended and all those in the wards when we visited were invited to participate; about one fifth declined, and no information on them is available. After data had been collected, for ease of analysis of pulmonary function test data, the study population was restricted to white subjects. This eliminated one heterozygote and seven control subjects, leaving 315 cystic fibrosis heterozygotes and 162 controls.
QUESTIONNAIRE
The ALA-DLD-78 questionnaire (basic version) was self administered. When help was requested, it was given in accordance with the directions of the epidemiology standardisation project. ' 
Results

SUBJECTS
The subjects completing the questionnaire are described in table 1. The cystic fibrosis heterozygotes were older than the control parents. Although somewhat more of the controls had never smoked (p = 0 08), the mean number of pack years consumed by the two groups did not differ. Sex distribution was similar in the two groups. Analyses of questionnaire answers were performed for the entire group of subjects and for subgroups stratified by sex and smoking habits. Non-smokers or never-smokers were defined as those who had not smoked (pack years = 0). SYMPTOM 
COMPLAINTS
Controls reported hay fever, dyspnoea, pneumonia, asthma, attacks of bronchitis, chronic bronchitis, and cough as frequently as cystic fibrosis heterozygotes (table 2) .
Cystic fibrosis heterozygotes reported the presence of lung disease before the age of 16 twice as frequently as controls (table 2). These differences were significant in the initial analysis (p = 0-03, Mantel-Haenszel extension of the x2 test). The relative risk for history of lung disease before age 16 was 2-27 for the heterozygotes (95% confidence interval 1 05-5-0). Correction, however, for the fact that answers to multiple questions not included in the original hypothesis were 
of heterozygotes but only 25% of controls had wheezed at some time (p < 0 05). Reports of wheeze among never-smokers were more common for both male and female heterozygotes and for all questions about wheeze (with a cold, apart from a cold, or most of the time) than among controls, but for the most part these differences did not reach significance. The age distribution of those who wheezed is statistically indistinguishable from the age distribution of those who deny wheezing for all subjects (cystic fibrosis heterozygotes and controls), for heterozygotes alone, and for heterozygotes and controls who never smoked. For example, wheezing was as common in heterozygote never-smokers over 50 years as in those under 50 (36% v 38%).
Heterozygous never-smokers who wheezed had lower FEV, and FEF25 -7 (% predicted) values" and a lower FEV,/FVC ratio than other non-smokers (table 4) . The FEVI/FVC ratio was lower in heterozygotes than controls whether they wheezed or not, but for the flows the interaction of heterozygosity for cystic fibrosis and the complaint of wheezing was significant, indicating that the complaint of wheezing among non-smoking heterozygotes identifies a subpopulation with reduced airflow. Although the same trends were evident for the entire study group and for smokers and non-smokers, they did not achieve statistical significance (table 5) .
Discussion
Parents of children with cystic fibrosis have increased airway reactivity to methacholine.9 Thirty per cent of heterozygotes but fewer than 5% of controls had their FEV, reduced by 20% in response to less than 3 mg/ml (PC2oFEVI < 3 mg/mI).9 The degree of airway reactivity, however, was for the most part mild. Among 50 heterozygotes with no admitted lung disease and normal baseline pulmonary function, the lowest PC2oFEV1 for methacholine was 0-6 mg/ml.9 This concentration, however, is only at the median PC20FEV, for a group of very mildly affected symptomless, unmedicated asthmatic subjects studied in the same laboratory at the same time (0 78 mg/ml). '6 For this reason, it may not be surprising that the excess prevalence of wheezing in the cystic fibrosis heterozygote population is small (table 3), and that there is no statistically significant increase in the prevalence of asthma (table 2) . Nevertheless, the complaint of wheezing among heterozygotes seems to have some functional significance, for it identifies a subgroup with reduced airflow ( Differences between the populations of heterozygotes and of controls unrelated to cystic fibrosis heterozygosity could produce more wheezing in heterozygotes. More heterozygotes than controls had smoked (table 1), but there is increased prevalence of wheezing even among those who had never smoked. Although the heterozygotes were older than controls (table 1) , there was no difference in the reports of wheezing between cystic fibrosis heterozygote neversmokers above age 50 and up to 50, and the age distribution of cystic fibrosis heterozygotes who wheeze is the same as that of cystic fibrosis heterozygotes who deny wheeze, both for the entire group and for the never-smokers. Thus neither smoking nor age differences between cystic fibrosis heterozygotes and controls account for the increased prevalence of wheezing in cystic fibrosis heterozygotes.
The altered home environment produced by a child with cystic fibrosis might promote wheezing in the parents. For example, exposure of some parents to pancreatic extract powder by inhalation during the child's infancy might sensitise the airway.'7 Since very few parents currently handling pancreatic extract powder were studied, for this explanation to be valid we must postulate an effect that extends beyond the period of exposure to account for the group differences. Moreover, since the introduction of microencapsulated pancreatic enzyme preparations, exposure of parents to aerosolised proteolytic enzymes has been greatly reduced. In the present study younger cystic fibrosis heterozygotes have a prevalence of wheezing similar to that of older heterozygotes (who were more likely to have been exposed to powdered pancreatic enzymes Early investigations of the occurrence of lung disease in cystic fibrosis heterozygotes did not detect differences from controls,36 probably for several reasons. Most earlier studies were looking for confirmed diagnoses of diseases (such as asthma, emphysema, chronic bronchitis, often strictly defined) in a young to middle aged population, but lacked the statistical power to detect even a twofold increase in their prevalence. In our study, respiratory symptoms as well as diagnoses confirmed by physicians were recorded for more than twice as many subjects as in any of the previous studies. Standardised and validated questionnaire instruments were not used for some of the earlier studies. Moreover, smoking habits were often not considered in the analysis of earlier data, and so real differences between the experimental and control populations might be obscured (or spurious differences introduced).
In summary, pulmonary abnormalities can be revealed in cystic fibrosis heterozygotes by methacholine, and the major symptom of increased airway reactivity-wheezing-is somewhat more prevalent among heterozygotes than among controls. Moreover, among heterozygotes the complaint of wheezing appears to identify a subgroup with reduced airflow (tables [4] [5] . If these abnormalities arise from a single abnormal gene for cystic fibrosis, then we can speculate that (1) the basic defect in cystic fibrosis is expressed in the lungs of heterozygotes and should be demonstrable in the appropriate test system; (2) one gene for cystic fibrosis is sufficient to produce mild lung abnormalities in the absence of infection, so the lung disease in patients homozygous for the disease is not solely the consequence of chronic bacterial infection; (3) study of heterozygotes (in whom the secondary consequences of infection and structural damage will not obscure the initiating events) may elucidate the pathogenesis of the lung disease in cystic fibrosis. Whether or not the cystic fibrosis gene itself contributes to airway reactivity, a subpopulation of heterozygotes, those who wheeze, appear to be at risk for poorer pulmonary function or development and progression (with an appropriate promoter) of chronic obstructive lung disease. This hypothesis can be tested directly in a study of a still larger number of heterozygotes and controls.
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